GLYC earnings call for the period ending December 31, 2018.
News & Analysis: GlycoMimetics
GLYC earnings call for the period ending June 30, 2018.
Despite good news about its lead drug, investors are rushing for the exits.
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
Updated data that was presented at a key blood conference is exciting investors.
New data from a trial evaluating one of its most promising drug candidates failed to impress investors.
The stock received yet another piece of good news this month -- this time, from Europe.
Optimism over a mid-stage leukemia drug in development is causing shares to climb this week.